Announcement on Preliminary Earnings Estimate for 2025

Earlier from Beijing Sun-Novo Pharmaceutical Research

• Announcement on Progress in Litigation Involved by the CompanyFeb 10
• Announcement on Terminating the Issuance of Shares and Convertible Corporate Bonds to Purchase Assets and Raising Supporting Funds and Related Party Transactions, and the Withdrawal of Application DocumentsJan 28
• Announcement on Voluntary Disclosure on the Acceptance of Clinical Trial Application for ABA001 InjectionJan 22
• Announcement on Litigation Results of the CompanyJan 17
• Announcement on Stock Repurchase, Shareholding Increase and Loan ExtensionJan 1

Later from Beijing Sun-Novo Pharmaceutical Research

• Announcement on Cooperative Investment with Private FundMar 3
• Announcement on Voluntary Disclosure of Obtaining Notice of Approval for Clinical Trials of BTP4327Mar 5
• Announcement on Voluntary Disclosure of External InvestmentMar 10
• Announcement on the Self-Inspection Report on Insider Trading During the Self-Inspection Period by Persons Aware of Material Non-public Information Related to the Termination of Issuance of Shares and Convertible Corporate Bonds to Acquire Assets, Raising Supporting Funds, and Related Party TransactionsMar 14
• Announcement on Postponing Term Change of the Board of Directors and Resignation upon Term Expiration of Partial Independent DirectorsMar 21